How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,814 results for

Adrenal Mass

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

3541. Characterization of an atypical lipoprotein-binding protein in human aortic media membranes by ligand blotting. Full Text available with Trip Pro

human aortic media (and cultured human smooth-muscle cells) contain a major lipoprotein-binding protein with an apparent molecular mass of 105 kDa. Anionized preparations (carbamoyl- and acetyl-) of LDL, which did not displace 125I-LDL bound to the apo B,E receptor of cultured fibroblasts, were also recognized as ligands for the 105 kDa protein in aortic media membranes. LDL binding to 105 kDa protein was decreased in the presence of high density lipoprotein (HDL), although more than 100-fold molar (...) excess of HDL was required to achieve 50% displacement of bound LDL. The LDL-binding activity of 105 kDa protein was inhibited by EDTA, and was also significantly decreased when samples were reduced by beta-mercaptoethanol before electrophoresis. Monoclonal antibodies against apo B,E receptor reacted with partially purified bovine adrenal apo B,E receptor, but not with 105 kDa protein of human aortic media membranes. The spectrum of properties of this vascular smooth-muscle lipoprotein-binding

1994 Biochemical Journal

3542. The Mr 80,000 common forms of neurophysin and vasopressin from bovine neurohypophysis have corticotropin- and β-endorphin-like sequences and liberate by proteolysis biologically active corticotropin Full Text available with Trip Pro

The Mr 80,000 common forms of neurophysin and vasopressin from bovine neurohypophysis have corticotropin- and β-endorphin-like sequences and liberate by proteolysis biologically active corticotropin We have tested the hypothesis that the high M(r) forms common to both neurophysin and vasopressin detected in bovine neurohypophysis extracts (Nicolas, P., Camier, M., Lauber, M., Masse, M.-J. O., Möhring, J. & Cohen, P. (1980) Proc. Natl. Acad. Sci. USA 77, 2587-2591) might also contain (...) the elution volume of standard (125)I-labeled corticotropin-(1-24), was tested for its ability to activate glucocorticoid biogenesis by the amphibian interrenal tissue (adrenal) in perifusion. It was found to exhibit a noticeable activity qualitatively undistinguishable from the one of the reference human corticotropin-(1-39). The name neurohypophyseal "coenophorin" (from the Greek word for common) is proposed for this class of M(r) 80,000 polypeptides that might represent the common precursor store-house

1981 Proceedings of the National Academy of Sciences of the United States of America

3543. Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes Full Text available with Trip Pro

cells to bind LDL is enhanced threefold when cocultured with astrocytes. We next investigated the ability of astrocytes to modulate endothelial cell LDL receptor expression. We have shown that the lipid requirement of astrocytes increases the expression of endothelial cell LDL receptors. Experiments with dialysis membranes of different pore size showed that this effect is mediated by a soluble factor(s) with relative molecular mass somewhere between 3,500 and 14,000. Substituting astrocytes (...) with smooth muscle cells or brain endothelium with endothelium from the aorta or the adrenal cortex did not enhance the luminal LDL receptor expression on endothelial cells, demonstrating the specificity of the interactions. This factor(s) is exclusively secreted by astrocytes cocultured with brain capillary endothelial cells, but it also upregulates the LDL receptor on other cell types. This study confirms the notion that the final fine tuning of cell differentiation is under local control.

1994 The Journal of cell biology

3544. Molecular cloning, functional expression and pharmacological characterization of a mouse melanocortin receptor gene. Full Text available with Trip Pro

Molecular cloning, functional expression and pharmacological characterization of a mouse melanocortin receptor gene. We describe the cloning of the mouse HGMP01A gene that encodes a melanocortin receptor functionally distinct from the adrenal cortex corticotropin (adrenocorticotrophic hormone; ACTH) receptor and the melanocyte-stimulating hormone (MSH) receptor expressed in melanoma. The gene encodes a protein of 323 amino acids with a calculated molecular mass of 35,800 Da, displaying (...) potential sites for N-linked glycosylation and phosphorylation by protein kinase C. An RNAase protection assay detected weak expression in the brain, but not in adrenal gland, skin, or any of the other tissues tested. Stable CHO cell lines expressing over 100,000 receptors per cell were generated. The recombinant receptor binds iodinated [Nle4,D-Phe7]alpha-MSH (NDP-MSH) with an apparent Kd of 700 pM. Displacement of the ligand by a variety of pro-opiomelanocortin-derived peptides revealed

1994 Biochemical Journal

3545. Gordon Wilson lecture. The prevention of immune rejection of islet transplants without the use of immunosuppressive drugs. Full Text available with Trip Pro

to the prevention of rejection of islet allografts in the dog. Thus the problems remaining with respect to human application are two. One is to determine which of the six methods will completely prevent rejection of islet allografts in dogs and could serve as a model for human application. The second is to modify and adapt the Velcro technique and the automated procedure for mass isolation of islets to the human pancreas. When we have been successful in modifying these isolation procedures so that we can obtain (...) at least 100-150,000 islets, then human islets will be transplanted into the omentum of diabetic subjects who have received a kidney transplant and are already being treated with immunosuppressive agents. The purpose of these initial studies in humans will be to determine whether a sufficient mass of endocrine islet tissue has been transplanted to maintain normoglycemia and normal carbohydrate metabolism in these individuals. We hope that by the time these studies are completed we will have finished

1984 Transactions Of The American Clinical And Climatological Association

3546. Mastocytoma in a cow: a case report. Full Text available with Trip Pro

Mastocytoma in a cow: a case report. Mastocytoma was diagnosed in a four year old Holstein cow. The enlarging mass was clinically determined to be metastatic to the right superficial cervical lymph node. Cytological examination of both sites revealed mast cell neoplasia. Histopathological examination confirmed the presence of this tumor in these same sites as well as in liver, kidney and adrenal. Ultrastructurally, the mass contained round cells with electron dense granules in the cytoplasm.

1984 Canadian Journal of Comparative Medicine

3547. Prepubertal Girls with Premature Adrenarche Have Greater Bone Mineral Content and Density Than Controls Full Text available with Trip Pro

Prepubertal Girls with Premature Adrenarche Have Greater Bone Mineral Content and Density Than Controls Body composition in premature adrenarche (PA) has not been described. We hypothesized that the increased adrenal androgens in PA would have a trophic effect on lean body components. We studied 14 PA subjects and 16 controls, all prepubertal Hispanic girls. The body composition parameters tested included height, weight, bone mineral density (BMD), bone mineral content (BMC), nonbone fat-free (...) mass, total body potassium, total body water, and extracellular water. Bone age was determined in all PA subjects. Compared with controls, PA subjects had significantly higher BMC (P = 0.02) and BMD (P = 0.03) when adjusted for age, weight, height, and fat mass, but were not different in the following lean body components: fat-free mass, total body potassium, total body water, and extracellular water. There was no difference in BMD or BMC between the PA subjects with and without advanced bone age

2001 The Journal of clinical endocrinology and metabolism

3548. Inositol 1,3,4,5-tetrakisphosphate binding sites in neuronal and non-neuronal tissues. Properties, comparisons and potential physiological significance. Full Text available with Trip Pro

and adrenal microsomes were used in a ligand-displacement mass assay (conducted under near-physiological conditions, at pH 7.0) on extracts of cerebral-cortex slices stimulated with agonists, and both preparations faithfully detected the increases in Ins(1,3,4,5)P4 that occurred, implying that Ins(1,3,4,5)P4 is the principal ligand on these binding sites in intact cells. 7. Apparent contradictions in the literature with regard to Ins(1,3,4,5)P4 binding sites in neuronal and peripheral tissues can (...) Inositol 1,3,4,5-tetrakisphosphate binding sites in neuronal and non-neuronal tissues. Properties, comparisons and potential physiological significance. 1. Ins(1,3,4,5)P4 binding sites were studied in cerebellar and hepatic microsomes from rat, and in bovine adrenal-cortical microsomes. 2. At pH 7.0, all three tissues showed specific binding, with Ins(1,3,4,5)P4 being the most potent competing ligand of those tested [which included Ins(1,4,5)P3, Ins(1,3,4,5,6)P5 and InsP6] and Scatchard

1992 Biochemical Journal

3549. The mechanism of calcium channel facilitation in bovine chromaffin cells. Full Text available with Trip Pro

The mechanism of calcium channel facilitation in bovine chromaffin cells. 1. This study was planned to clarify the mechanism of Ca2+ channel facilitation by depolarizing prepulses given to voltage-clamped bovine chromaffin cells. The hypothesis for an autocrine modulation of such channels was tested by studying the effects of a soluble vesicle lysate (SVL) on whole-cell Ba2+ currents (IBa). 2. SVL was prepared from a bovine adrenal medullary homogenate. The ATP content in this concentrated SVL (...) antagonized the effects of SVL. Treatment of SVL with alkaline phosphatase or dialysis against a saline buffer to remove low molecular mass materials (< 10 kDa) considerably reduced the activity of SVL. 6. Stopping the flow of the external solution (10 mM Ba2+) gradually reduced the size, and slowed down the activation phase, of the current. Prepulse facilitation of IBa was absent or weak in a superfused cell, but was massive upon flow-stop conditions in the presence or absence of 3 microM nifedipine. 7

1996 The Journal of physiology

3550. Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis

distribution- baseline and 8 months Eye examinations for cataracts and glaucoma - baseline and 8 months Bone density scan (DEXA scan) of the lower spine and hip - baseline, 4 and 12 months Magnetic resonance imaging (MRI) of the hips Psychological evaluation and quality of life evaluation - baseline, 1, 2 and 8 months Blood tests for adrenal gland function - baseline, 4 and 8 months Blood and urine tests - 10, 12, 15, and 18 months Patients who achieve remission (whose urine protein levels decrease (...) Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria INCLUSION CRITERIA: Adults and children. Biopsy proven FSGS, including idiopathic FSGS and collapsing FSGS, but excluding HIV-associated FSGS and secondary FSGS associated with morbid obesity, sickle cell anemia, reflux nephropathy, chronic tubular injury, congenital renal anomalies, and reduced nephron mass. Glomerular filtration rate will be estimated using 4 variable MDRD GFR

2000 Clinical Trials

3551. Capecitabine in Treating Patients With Malignant Mesothelioma

at largest diameter with conventional techniques or at least 10 mm with spiral CT scan The following are not considered measurable disease: Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal masses not confirmed and followed by imaging techniques Cystic lesions Tumor lesions located in a previously irradiated area PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 or 1 Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 (...) CONCURRENT THERAPY: Biologic therapy: Concurrent epoetin alfa allowed Chemotherapy: No prior systemic cytotoxic chemotherapy for malignant mesothelioma Prior intrapleural cytotoxic or sclerosing agents (including bleomycin) allowed No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy except the following: Steroids administered for adrenal failure Hormonal therapy administered for nonmalignant conditions (e.g., insulin for diabetes) Intermittent use of dexamethasone

2000 Clinical Trials

3552. Positron Emission Tomography for Detecting Non-small Cell Lung Cancer

diagnosed by transbronchial biopsy, and if a separate ipsilateral lung lesion is clearly evident on radiographs, biopsy of the lung tumor is not required for this patient. OR c) Patient may be eligible without histologic or cytologic proof if; The patient is strongly suspected to have primary bronchogenic carcinoma (e.g., heavy smoker with a new peripheral mass with typical appearance of lung cancer on chest radiograph although bronchoscopy and/or fine needle aspiration is nondiagnostic), and The tumor (...) representative prior to study participation. Female patient of childbearing potential must have a negative serum or urine pregnancy test, 72 hours prior to FDG-PET. NOTE: This is in order to avoid unnecessary fetal radiation exposure and because the use of furosemide is contraindicated in pregnancy. Patient must complete the following standard staging procedures 60 days prior to registration. CT scan of the chest and upper abdomen (include adrenals) with contrast NOTE: Non-contrast CT scan may be used

1999 Clinical Trials

3553. Heart Disease Risk Factors in Major Depression

resistance in each patient and control, we will apply the hyperinsulinemic euglycemic glucose clamp procedure. This is the gold standard method for measuring the insulin sensitivity since it reflects the direct human body glucose metabolic response to a known insulin infusion. Moreover, it is essential to use this technique in patients with major depression as data indicate that other alternative procedures give unreliable results in the context of hypercortisolism. Condition or disease Adrenal Gland (...) . Subjects should not have significant underlying illnesses known to affect insulin sensitivity, and should have a body mass index between 20 and 30 kg/m2. EXCLUSION CRITERIA Pregnancy Existing diabetes mellitus Body mass index less than 20 or greater than 30 kg/ m2 Existing cardiovascular diseases and other end organ diseases Existing peripheral vascular disease HIV infection Patients who are on B-blockers, thiazides, and/or glucocorticoids and cannot discontinue these medications. Subjects who

2000 Clinical Trials

3554. Risk of Coronary Heart Disease in Women With Polycystic Ovary Syndrome

, physical exam, and hormone studies was made. In addition, information on the number of pregnancies, number of live births, menstrual history, and history of surgical or natural menopause was obtained. Women with evidence of thyroid, adrenal or pituitary disease were excluded. The grant was renewed in 1996 to determine whether women with PCOS have evidence of an increased prevalence rate of subclinical atherosclerosis. Within the PCOS population the investigators performed five studies to further (...) -to-hip ratio and body mass index (BMI). Fourth, they assessed differences in body composition between PCOS cases and control women, including intra-abdominal fat as measured by computed tomography (CT) of the abdomen and sagittal diameter, and percent body fat as measured by dual energy x-ray absorptiometry (DEXA). They evaluated the relationship between subclinical atherosclerosis and body composition separately for cases and for controls. Previous studies had clearly shown that PCOS women were

2000 Clinical Trials

3555. Diagnosis and Treatment of Pheochromocytoma

to Brief Summary: Pheochromocytoma is a tumor of the adrenal gland. This tumor is typically benign (not cancerous) and can be cured by surgical removal. However, pheochromocytomas produce neurohormones called cateholamines (epinephrine and norepinephrine). High levels of catecholamines can result in high blood pressure, headaches, sweating, heart palpitations, nausea, vomiting, and other symptoms. These tumors are considered dangerous because of their unpredictable behavior. Patients (...) information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Patients of any age and either sex who are suspected of having a pheochromocytoma on the basis of one or more of the following: 1. hypertensive episodes in a normotensive subject, 2. abnormal levels of blood and/or urinary catecholamines or their metabolites, or 3. an otherwise unexplained abdominal mass. Patients without any evidence of pheochromocytoma are excluded

1999 Clinical Trials

3556. Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

not considered measurable include the following: Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal masses not confirmed and followed by imaging techniques Cystic lesions Tumor lesions in a previously irradiated area No clinically suspected or confirmed supraclavicular lymph node metastases No pleural effusions visible on plain chest radiographs, regardless of cytology PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified (...) and be considered to be at less than 30% risk of relapse PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent filgrastim (G-CSF) during consolidation therapy Chemotherapy: No prior chemotherapy for small cell lung cancer No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy except: Steroids for adrenal failure Hormones for non-disease-related conditions (e.g., insulin for diabetes) Intermittent use of dexamethasone as an antiemetic or as an adjunct to prophylactic cranial

2002 Clinical Trials

3557. Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

disease Ascites Pleural/pericardial effusion Abdominal masses not confirmed and followed by imaging techniques Cystic lesions Tumor lesions in a previously irradiated area Controlled CNS metastases allowed if patient is neurologically stable and off steroids PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal (...) for diabetes) No concurrent steroids except for adrenal failure Radiotherapy: See Disease Characteristics Prior radiotherapy for symptomatic lesions or those that might produce disability (e.g., painful bone metastases) allowed if other measurable disease present At least 4 weeks since prior radiotherapy No concurrent palliative radiotherapy Surgery: See Disease Characteristics Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor

2001 Clinical Trials

3558. Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid

Drug: Cholic Acids 10-15 mg/kg body weight/day taken orally. Other Names: Cholic Cholic Acid Cholic Acid Capsules Outcome Measures Go to Primary Outcome Measures : Determination of changes in synthesis of atypical bile acids in urine by mass spectrometry (FAB MS) [ Time Frame: 12 months ] Secondary Outcome Measures : Change in Liver Function Test (serum transaminases) [ Time Frame: Standard of Care ] Change in Liver Histology (for patients in whom biopsy was performed) [ Time Frame: Standard (...) Disorders, Nervous System Metabolism, Inborn Errors Metabolic Diseases Adrenal Insufficiency Adrenal Gland Diseases Endocrine System Diseases Liver Diseases

2000 Clinical Trials

3559. PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal masses that are not confirmed and followed by imaging techniques Cystic lesions No known brain metastases PATIENT CHARACTERISTICS: Age Over 18 Performance status ECOG 0-1 Life expectancy Not specified Hematopoietic Granulocyte count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic Bilirubin no greater than 1.5 times upper limit of normal (ULN) AST no greater than 2.5 times ULN (...) therapy No concurrent hormonal therapy except steroids for adrenal failure or hormones for non-disease-related conditions (e.g., insulin for diabetes) Radiotherapy See Disease Characteristics At least 4 weeks since prior radiotherapy No concurrent palliative radiotherapy Surgery See Disease Characteristics At least 2 weeks since prior major surgery Other At least 30 days since prior investigational agents At least 7 days since prior grapefruit or grapefruit juice At least 7 days since prior CYP3A4

2003 Clinical Trials

3560. Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

neuroblastoma are also eligible All patients must have completed therapy including intensive induction followed by ASCT and radiotherapy to be eligible for ANBL0032; radiotherapy may be waived for patients who either have small adrenal masses which are completely resected up front, or who never have an identifiable primary tumor; examples of such therapies include: Following treatment per A3973 protocol Following treatment per Pediatric Oncology Group (POG)-9341/9342 protocol Following treatment per CCG3891

2001 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>